Ingeniería de Tejidos y Medicina Regenerativa Cardíaca
CTE
Hospital Clinic Barcelona
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital Clinic Barcelona (21)
2024
-
An atlas of cells in the human tonsil
Immunity, Vol. 57, Núm. 2, pp. 379-399.e18
-
Natural Hydrogels Support Kidney Organoid Generation and Promote In Vitro Angiogenesis
Advanced Materials, Vol. 36, Núm. 34
2023
2022
-
A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells
Cell Metabolism, Vol. 34, Núm. 6, pp. 857-873.e9
-
Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study
European Journal of Cancer, Vol. 174, pp. 243-250
-
Prognostic impact of micromegakaryocytes in primary myelodysplastic syndromes
Leukemia and Lymphoma, Vol. 63, Núm. 5, pp. 1227-1235
2021
-
Dynamics of genome architecture and chromatin function during human B cell differentiation and neoplastic transformation
Nature Communications, Vol. 12, Núm. 1
2020
-
Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma
Leukemia, Vol. 34, Núm. 11, pp. 3007-3018
-
The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome
Nature Cancer, Vol. 1, Núm. 11, pp. 1066-1081
2018
-
The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia
Nature Medicine, Vol. 24, Núm. 6, pp. 868-880
2017
-
Differentiation stage of myeloma plasma cells: Biological and clinical significance
Leukemia, Vol. 31, Núm. 2, pp. 382-392
2016
-
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under lendex: A longitudinal analysis
Blood, Vol. 127, Núm. 9, pp. 1151-1162
-
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial
The Lancet Oncology, Vol. 17, Núm. 8, pp. 1127-1136
2014
-
Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis
PLoS ONE, Vol. 9, Núm. 12
-
Sequential Third-Party Mesenchymal Stromal Cell Therapy for Refractory Acute Graft-versus-Host Disease
Biology of Blood and Marrow Transplantation, Vol. 20, Núm. 10, pp. 1580-1585
2013
-
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma
New England Journal of Medicine, Vol. 369, Núm. 5, pp. 438-447
2012
-
A DNA methylation fingerprint of 1628 human samples
Genome Research, Vol. 22, Núm. 2, pp. 407-419
2011
-
Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: Results of a phase I/II clinical trial
Haematologica, Vol. 96, Núm. 7, pp. 1072-1076
2010
-
Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma
Clinical Cancer Research, Vol. 16, Núm. 12, pp. 3260-3269
-
Utilización de bisfosfonatos en pacientes con mieloma múltiple: recomendaciones del comité de expertos del Grupo Español de Mieloma del Programa Español de Tratamientos en Hematología
Medicina Clinica, Vol. 134, Núm. 6, pp. 268-278